SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

GlaxoSmithKline plc. (7/12/18). "Press Release: James Ford Appointed GSK General Counsel". London.

Organisation Organisation GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
Products Product legal services
  Product 2 pharmaceutical

GSK today announced that James Ford, currently SVP and General Counsel for Global Pharma, will succeed Dan Troy as General Counsel, GSK. James will join the Corporate Executive Team (CET) on 1 August.

Through his 23-year career with GSK, James has gained wide-ranging legal experience including investigations, complex corporate transactions and litigation in senior roles across the USA, Asia and UK.

James replaces Dan Troy who will leave GSK after 10 years as General Counsel.

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

For further information please visit

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2017.

Record changed: 2018-07-18


Picture [LSUS] – The Business Web Portal 600x60px

More documents for GlaxoSmithKline (GSK) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top